Last reviewed · How we verify

NCT07292116

Disease Progression in ms

Not yet recruiting Last updated 18 December 2025
What this trial tests

trial in Prediction of Disease Progression in 53 participants. Not yet recruiting.

Timeline
15 December 2025
Primary endpoint
20 December 2025
1 March 2026

Quick facts

Lead sponsorHüseyin Bektaş
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment53
Start date15 December 2025
Primary completion20 December 2025
Estimated completion1 March 2026

Conditions studied

Sponsor

Hüseyin Bektaş

Who can join

18 and older, any sex, with Prediction of Disease Progression or Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Demographic and clinical data will be obtained from people with MS. Based on this data, the progression of the disease will be predicted with artificial intelligence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07292116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing